Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

Q. In a recent article about the challenges of treating eczema (atopic dermatitis), you described a number of over-the-counter treatments as well as modern prescription medicines. In particular, you ...

Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent. Learn more about APGE stock ...

Speedskater Erin Jackson, who won a gold medal at the 2022 Beijing Winter Olympics, talks about how eczema has affected her, ...

(HealthDay News) — Dupixent (dupilumab) has been approved by the US Food and Drug Administration to treat moderate-to-severe eczema that isn’t well controlled by topical medication. The active ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved their blockbuster medicine, Dupixent, for children six months to five years of age with severe atopic ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

The European Commission (EC) approved Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals' (NASDAQ:REGN) Dupixent to treat severe atopic dermatitis (eczema) in children aged six months to five years old ...

A mum has opened up about her daughter’s eczema struggles, saying it was heartbreaking to see her baby’s sheets splattered ...

Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent ...

Danielle Jonas spoke to Insider about her experience with moderate eczema. Jonas said she was "uncomfortable with myself," before using Dupixent as a treatment for her condition. Because of her eczema ...